Ophthalmic Drugs Market Forecast 2014-2024 - Exec

Ophthalmic Drugs Market Forecast
2014-2024
Prospects for Leading Companies
©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior
written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way
any of the material contained in this report. Each purchase and single copy is for personal use only.

www.visiongain.com Page 43
Ophthalmic Drugs Market Forecast 2014-2024:
1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
The world market for ophthalmic drugs will reach $20,922m in 2014. Led by blockbuster wet AMD
drugs Lucentis and Eylea, the ophthalmic drugs market is expected to grow significantly during the
forecast period. While some areas of the market, such as glaucoma, have been in decline due to
patent expiry and generic competition, the strong R&D pipeline in ophthalmology will drive growth
especially in the retinal disorders segment. The dry eye market will also grow more than previously
expected after early generic competition for the leading drug Restasis failed to materialise.
“Successful harnessing of the opportunities for growth in the
ophthalmic pharmaceutical market from 2014 to 2024 will depend
upon the development of novel products with technologies that
increase clinical effectiveness and development of products for
previously-untreated ophthalmic conditions...”
Thomas Ling, senior pharmaceutical and medical devices industry analyst,
visiongain 2014
Figure 1.1 Global Causes of Visual Impairment (% of cases), 2012
Uncorrected
refractive errors,
43%
Cataracts, 33%
Glaucoma, 2%
Diabetic
retinopathy, 1%
Corneal
opacities, 1%
Age-related
macular
degeneration, 1%
Trachoma, 1% Undetermined
causes, 18%
Source: visiongain 2014; World Health Organization

Figure 1.2 World 65+ Population Forecast: Size (m), CAGR (%), by National Market,
2013-2024
1.2 Global Ophthalmic Drugs Market Segmentation
Figure 1.3 Global Ophthalmic Drugs Market Segmentation Overview, 2014
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
0
50
100
150
200
250
300
350
CAGR(%)
Population(m)
National Market
65+ Population (m) 2013 65+ Population (m) 2024 CAGR (%) 2013-2024
Leading DrugsKey SegmentsMarket
Ophthalmic
Drugs
Retinal Disorders Lucentis, Eylea, Avastin
Allergic, Inflammatory
and Infective Drugs
Pataday,Vigamox, Patanol
Glaucoma
Lumigan and Ganfort,
Xalatan/Xalacom,
Travatan/Travatan Z
Dry Eye
Restasis, Refresh,
Hyalein, Diquas
Source: visiongain 2014
Source: United Nations Department of Economic and Social Affairs, Population Division, 2012; visiongain 2014

1.3 Why You Should Read This Report
This comprehensive report will:
• Enhance your strategic decision making
• Assist with your research, presentations and business plans
• Show which emerging market opportunities to focus on
• Increase your industry knowledge
• Keep you up-to-date with crucial market developments
• Allow you to develop informed growth strategies
• Build your technical insight
• Illustrate trends to exploit
• Strengthen your analysis of competitors
• Provide risk analysis, helping you avoid the pitfalls other companies could make
• Ultimately, help you to maximise profitability for your company.
1.4 How This Report Delivers
The report delivers considerable added value by revealing:
• Global market forecasts and analysis covering the period 2014 to 2024
• Regional and national market forecasts and analysis from 2014 to 2024
• Analysis of pipeline therapies and how these will shape the market
• Explanation of political, regulatory and technical factors to consider
• Submarket forecasts for 2014 to 2024
• Full transcripts of exclusive visiongain interviews with key opinion leaders in the market
• Profiles of leading companies operating within the market
• SWOT analysis of the major strengths and weaknesses of the market, together with the
opportunities available and the key threats faced
• Conclusions and recommendations

Table 1.1 Leading National Ophthalmic Drugs Market Forecast 2014 ($m, AGR%)
CAGR (%)
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2013-2024
World Ophthalmic
Drugs Market ($m)
- - - - - - - - - - - -
AGR (%) - - - - - - - - - - - -
US ($m) 2,000 - - - - - - - - - - -
AGR (%) - - - - - - - - 3.5 4.0 4.7 -
Japan ($m) - - - - - - - - - - - -
AGR (%) 6.5 7.2 - - - - - - - - 3.0 -
China ($m) - - - - - - - - - - - -
AGR (%) 11.4 - - - - - - - - 3.5 4.1 -
Germany ($m) - - - - - - - - - - - -
AGR (%) 5.7 - - - - - - - - 7.5 6.5 -
France ($m) 1,278 - - - - - - - - - - -
AGR (%) 5.5 5.5 - - - - - - - - 9.0 4.1
UK ($m) - - - - - - - - - - - -
AGR (%) 4.1 4.6 - - - - - - - - 2.5 -
Italy ($m) - - - - - - - - - - - -
AGR (%) 4.5 5.0 - - - - - - - - 4.7 -
Spain ($m) 450 - - - - - - - - - - -
AGR (%) 3.3 - - - - - - - - 4.7 5.4 -
Brazil ($m) - - - - - - - - - - - -
AGR (%) 3.2 - - - - - - - - 4.9 4.1 -
Russia ($m) 210 - - - - - - - - - - -
AGR (%) - - - - - - - - 3.3 3.2 3.4 4.1
India ($m) - - - - - - - - - - - 550
AGR (%) - - - - - - - - 3.6 2.6 7.5 -
Mexico ($m) - - - - - - - - - - - 250
AGR (%) 5.3 - - - - - - - - 5.4 5.6 -
Rest of the World ($m) - - - - - - - - - - - 120
AGR (%) 2.4 - - - - - - - - 7.0 7.5 -
1.5 Key Questions Answered by This Analytical Report
• How is the ophthalmic drugs market evolving?
• What is driving and restraining the ophthalmic drugs market?
• What are the market shares of each segment of the overall ophthalmic drugs market in
2014?
• How will each ophthalmic drugs submarket segment grow over the forecast period and
how much revenue will these submarkets account for in 2024?
• How will the market shares for each ophthalmic drugs submarket develop from 2014-
2024?
• Which individual therapies will prevail and how will these shifts be responded to?
• What will be the main driver for the overall market from 2014-2024?
• How will political and regulatory factors influence the regional markets and submarkets?
Source: visiongain 2014. Note: Actual data has been redacted in this data table. Values are for illustrative
purposes only.

• Will leading national ophthalmic drugs markets broadly follow the macroeconomic
dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2024 and which
geographical region will lead the market in 2024?
• Who are the leading players and what are their prospects over the forecast period?
• What are the predictions for M&A activity, consolidation for existing players and the
potential prospects for new market entrants?
• How will the industry evolve during the period between 2014 and 2024?
Visiongain understands that the ophthalmic drugs market will register strong growth. This report
examines in detail the market by region, by submarket, and as a whole, and provides the reader
with a thorough overview of the market to identify key growth areas and business opportunities to
exploit. This is where visiongain adds value.
1.6 Who is This Report For?
Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies will prove
invaluable for anyone wanting to better understand the industry and its underlying dynamics. It will
prove useful for businesses who wish to expand into different sectors or explore a new region for
expansion of their existing operations. The report comprehensively lays out the market drivers,
restraints, forecasts, technologies, investments, risks, trends, and leading companies and their
strategies to help the reader formulate a better-informed business strategy. This report will be ideal
for senior executives, business development managers, marketing managers, consultants, CEOs,
CIOs, COOs, Directors and others. Furthermore, governments, agencies and organisations will
also find value in our research report.
1.7 Methodology
Visiongain reports are compiled using a rich mixture of both primary and secondary information to
produce an overall industry outlook. The secondary and primary research is blended together to
produce a cohesive research report. The skill of the analyst is in meticulously sifting through vast
amounts of available information to produce a cohesive industry outlook that is well argued and
which, due to its breadth of sources, is comprehensive in outlook. This is where visiongain’s
expertise really adds value. Visiongain believes this proven research methodology, reinforced with
the views of industry experts, produces an accurate and objective market analysis.

Primary Research
In order to provide our clients with the best product possible, visiongain analysts interview several
market-leading companies and industry experts for each research report. Interviews cover a broad
range of issues from detailed technical product issues to insight into factors driving the industry at
the local and macroeconomic level. Further supporting interviews are also sourced from other
industry stakeholders. These interviews are fully transcribed and published in full within our
reports. Visiongain passionately believes that only by consulting extensively with industry can
thorough and accurate research be produced.
Secondary Research
Secondary research is performed by analysing hundreds of contracts / sales data from a multitude
of sources including company annual reports, SEC filings, contractual announcements, sales
reports, company web sites, news reports, online and in-house databases, industry journals, and
other statistical publications. By using a vast array of sources and not relying upon one single
source of data visiongain more accurately triangulates upon the reality of a market.
Market Evaluation & Forecasting Methodology
Market evaluation uses the bottom-up approach which involves analysing hundreds of contracts
and/or sales data from a multitude of sources such as annual reports, online and in-house
databases, industry journals, and other statistical publications and also by consulting with leading
industry experts. Regional market share data and company market share data are also derived
from a similar bottom-up data analysis process.
The extensive secondary data sources are then synthesised with the primary research insight from
company interviews and blended with the SWOT analysis to develop the forecasts. The experience
of the analyst allows them to consider historical precedent and assess growth rates on a year-by-
year basis, forming a clear vision of the future sector over a 10-year horizon providing a clear and
informed projection of future market prospects. This is the value of a visiongain report.

1.8 Frequently Asked Questions (FAQ)
• How are the market forecasts produced?
Please refer to our methodology in the previous section 1.7.
• Why do you not show the sources for your data?
In the vast majority of cases, the market data revealed is our own visiongain data compiled from
a very broad combination of our own in-house databases, our own market evaluation, company
annual reports, other secondary data and our primary research. In cases where the data is
being quoted directly, the source is credited to the organisation or source of data.
• Why does the report not provide market forecasts for all national markets? Why are
some countries not included?
The aim of the report is to identify the leading national markets so the reader can assess where
the greatest business potential will be. Furthermore, in some cases there is insufficient data or
the data available does not meet our high quality threshold, hence we decide not to include it.
• Does the report provide year-by-year market forecasts for the leading national markets?
Yes, the report quantifies the leading national markets in $m each year with AGR (%).
• Does the report just contain market forecasts or do they also contain supporting written
analysis explaining the reasons behind the forecast?
Yes, the supporting text explains the forecast and provides context to justify our forecast.
• Why are not all of the regions or countries segmented by application or technology?
We aim to provide clients with the best possible information available that we believe can be
relied upon. However, in some cases, this extra detail or ‘granularity’ is not possible or the data
available is not reliable enough to meet our high quality threshold, hence we decide to omit it.
• Why does the report not mention every single company in the sector?
Our report is primarily a market forecast report to assist investment decisions and therefore
focuses upon the market evaluation, forecasts and the demand-side factors. As such our report
is not intended to be an exhaustive business directory. However, we do profile a selection of the
leading 10 to 20 major companies operating within the sector.
• How is the report delivered?
PDF format is the favoured option as it is instant, secure and easily used across multiple
platforms, PCs, laptops, tablets and even smartphones, allowing you to view content while in
the office or on the move.

1.9 Associated Visiongain Reports
Visiongain has an extensive range of other pharmaceutical and medical devices industry reports
which may be of interest to you. Please consider the following report titles:
Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024
https://www.visiongain.com/Report/1186/Pharma-Leader-Series-Top-25-
Ophthalmic-Drug-Manufacturers-2014-2024
Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market
2014-2024
https://www.visiongain.com/Report/1236/Needle-Free-Delivery-Technology-and-
Market-Forecast-2014-2024
Ophthalmic Devices Market Forecast 2014-2024: Future Prospects for Leading
Companies
https://www.visiongain.com/Report/1272/Ophthalmic-Devices-Market-Forecast-
2014-2024
Next-Generation Biologics R&D, Industry and Market 2014-2024
https://www.visiongain.com/Report/1235/Next-Generation-Biologics-R-D-Industry-
and-Market-2014-2024
World Biological Drugs Market 2013-2023
https://www.visiongain.com/Report/1048/World-Biological-Drugs-Market-2013-2023
Diabetes Treatments: World Drug Market 2013-2023
https://www.visiongain.com/Report/1033/Diabetes-Treatments-World-Drug-Market-
2013-2023
Drug Delivery Technologies: Commercial Prospects 2013-2023
https://www.visiongain.com/Report/1042/Drug-Delivery-Technologies-Commercial-
Prospects-2013-2023

1.10 About Visiongain
Visiongain is one of the fastest-growing business intelligence providers helping you keep abreast
of key changes taking place in your industry. Based in London, UK, visiongain publishes insightful
market reports produced by experienced in-house analysts, many of whom are educated to
Masters and PhD level and are experts in their field. Visiongain has achieved a reputation for
examining difficult, cutting-edge topics that other companies have yet to realise are significant
game-changers. Stay ahead with visiongain’s knowledge base. Visiongain has firmly established
itself as the first port of call for the business professional who needs independent, high quality,
original business intelligence to depend upon. Technology is moving rapidly so it is vitally important
that you understand the opportunities that lie ahead with changes in technologies, materials,
regulations and the evolving economic landscape. Visiongain produces insightful market reports
across a wide range of industry verticals including:
• Automotive
• Aviation
• Construction
• Defence
• Energy: Oil & Gas
• Food & Drink
• IT
• Maritime
• Medical Devices
• Metals
• Packaging
• Pharmaceuticals
• Plastics
• Renewable Energy
• Telecoms
• Utilities
By reading a visiongain report, or commissioning a piece of bespoke research, following our
industry Twitter feeds or subscribing to a visiongain newsletter, you will be better-informed, more
equipped to face the challenges and exploit the business opportunities that lie ahead. Stay abreast
of key issues affecting your industry. You will see clearly the growth prospects for your market and
how specific submarkets will develop over a 10-year forecast horizon. Visiongain's reports and
bespoke research are comprehensive market-based products with analyses and opinions which
will benefit your work, saving you time, informing your business strategy to allow you to exploit key
business opportunities to maximise profit and secure your company’s future prospects.

Ophthalmic Drugs Market Forecast 2014-2024 - Exec

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (14)

Ophthalmic Drugs Market Forecast 2014-2024 - Exec